Research programme: male infertility therapy - Enhance BiotechAlternative Names: BIO 316; BIO 317
Latest Information Update: 08 Jun 2010
At a glance
- Originator Enhance Biotech
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Male infertility
Most Recent Events
- 08 Jun 2010 Development discontinued for Male infertility during 2006
- 28 Oct 2005 Preclinical trials in Male infertility in USA (unspecified route)